AstraZeneca: SERENA-4 Phase 3 Trial Misses Progression-Free Survival Goal

Key Facts

AstraZeneca said the SERENA-4 Phase 3 trial did not meet its primary objective of a statistically significant improvement in progression-free survival. The study tested Etcamah, or camizestrant, with palbociclib as upfront treatment for estrogen receptor-positive, HER2-negative advanced breast cancer; a numerical improvement was observed but did not reach the statistical-significance threshold.

The global, randomized, double-blind SERENA-4 trial compared Etcamah plus palbociclib with anastrozole plus palbociclib. It enrolled 1,371 adults with locally advanced or metastatic disease who had received no systemic treatment for advanced disease.

The outcome means the trial did not demonstrate superiority under its prespecified statistical test; it does not mean the data showed no numerical difference. AstraZeneca's release did not disclose the size of the improvement or risk estimates, and the company said the data would be shared later.

The company said the safety profile of Etcamah plus palbociclib was consistent with the known profiles of both medicines, with no new safety concerns identified. Secondary endpoints included overall survival, time to a second progression and health-related quality of life.

The SERENA-4 result does not mean Etcamah is unapproved. The Food and Drug Administration granted accelerated approval on September 4, 2026, based on SERENA-6, for use upon detection of an ESR1 mutation during initial therapy with an aromatase inhibitor and a CDK4/6 inhibitor.

The distinction matters commercially and regulatorily: the current study tested Etcamah from the start of systemic treatment for advanced disease, while the U.S. approval applies after an ESR1 mutation is detected during therapy. Development continues in the CAMBRIA-1 and CAMBRIA-2 Phase 3 early-breast-cancer trials within a program involving about 10,000 patients.

U.S.-listed AZN closed at $159.09 on September 11, 2026, after trading between $158.18 and $161.50, according to EL7 data. The available data contain no daily percentage change or evidence tying the session's movement to the trial result, so they do not support characterizing the stock as pressured by the announcement.